Equities Analysts Offer Predictions for NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at Brookline Capital Management lowered their FY2027 EPS estimates for Intellia Therapeutics in a research note issued on Monday, October 27th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of $18.46 for the year, down from their prior forecast of $25.71. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Management also issued estimates for Intellia Therapeutics’ FY2028 earnings at $19.13 EPS and FY2029 earnings at $52.10 EPS.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The firm had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. During the same period in the previous year, the firm posted ($1.52) earnings per share. The business’s revenue was up 104.3% compared to the same quarter last year.

NTLA has been the subject of several other reports. Tudor Pickering set a $14.50 price target on shares of Intellia Therapeutics in a research note on Tuesday. Citizens Jmp raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a research note on Monday, October 6th. William Blair downgraded shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. JMP Securities decreased their price target on shares of Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating for the company in a research note on Tuesday. Finally, Chardan Capital decreased their price target on shares of Intellia Therapeutics from $60.00 to $48.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Twelve analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.74.

Intellia Therapeutics Trading Up 2.9%

NTLA opened at $12.62 on Thursday. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The company has a market cap of $1.35 billion, a P/E ratio of -2.69 and a beta of 2.37. The company has a fifty day moving average price of $17.12 and a two-hundred day moving average price of $12.31.

Insider Activity

In related news, CAO Michael P. Dube sold 1,871 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer directly owned 55,266 shares in the company, valued at approximately $960,523.08. The trade was a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William J. Chase bought 100,000 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was bought at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC boosted its stake in Intellia Therapeutics by 3.8% in the first quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company’s stock valued at $92,508,000 after acquiring an additional 474,629 shares during the last quarter. Vanguard Group Inc. boosted its stake in Intellia Therapeutics by 5.5% in the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company’s stock valued at $76,447,000 after acquiring an additional 561,978 shares during the last quarter. Geode Capital Management LLC boosted its stake in Intellia Therapeutics by 5.1% in the second quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company’s stock valued at $24,449,000 after acquiring an additional 126,049 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Intellia Therapeutics by 73.0% in the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock valued at $8,822,000 after acquiring an additional 396,858 shares during the last quarter. Finally, Armistice Capital LLC boosted its stake in Intellia Therapeutics by 78.6% in the second quarter. Armistice Capital LLC now owns 650,000 shares of the company’s stock valued at $6,097,000 after acquiring an additional 286,000 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.